Modern therapeutic modalities enabling preservation of procreative potential in women treated for genital malignancies
Affiliation and adress for correspondence

Correspondence to: Klinika Nowotworów Narządów Płciowych Kobiecych, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, ul. Roentgena 5, 02-781 Warszawa
Source of financing: Department own sources

GIN ONKOL 2006, 4 (4), p. 230-240

Recent decade saw a significant progress in the diagnosis of prognostically important features of neoplasm, in particular those influencing critically the choice of techniques and protocols of oncological treatment. Principles of therapeutic approach to patients with genital malignancies, which were valid in the past, most often neither took into consideration the age of patients, nor was the issue of preservation of procreative functions considered as clinically important. In recent years, the situation in this area underwent a dramatic change. In patients of procreative age, the measure of therapeutic success is not as much standard parameters, e.g. long-term survival rate or recurrence risk, but rather overall quality of life and in particular preservation of ability to procreate. At present, in most locations of early-stage female genital malignancy, there is a possibility to spare procreative function. Based on reports in recent publications, we undertook a review of current views on management of malignancies of uterine cervix, uterine mucosa and ovary enabling preservation of procreative potential of women involved.

Keywords: uterine cervix cancer, endometrial cancer, ovarian cancer, sparing treatment, preservation of fertility